Cargando…

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

BACKGROUND: Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ipilimumab, baseline characteristics and changes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wenshi, Yu, Daohai, Sarnaik, Amod A, Yu, Bin, Hall, Maclean, Morelli, Dawn, Zhang, Yonghong, Zhao, Xiuhua, Weber, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527361/ https://www.ncbi.nlm.nih.gov/pubmed/22788688 http://dx.doi.org/10.1186/1479-5876-10-146

Ejemplares similares

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
por: Mullinax, John E., et al.
Publicado: (2018)

Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma
por: Garg, Saurabh K., et al.
Publicado: (2023)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2017)

Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma
por: Han, Dale, et al.
Publicado: (2015)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
por: Toomey, Paul, et al.
Publicado: (2013)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
por: Verschraegen, Claire
Publicado: (2012)

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
por: Hahn, Laura, et al.
Publicado: (2016)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK
por: Larkin, James, et al.
Publicado: (2015)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o7s5knk66tboq53ebuiic3tbhe